High impact
Benralizumab (Fasenra) (CPB 0925, reviewed 2025-12-23)
Aetna·Effective Dec 23, 2025
Aetna updated its Clinical Policy Bulletin (CPB 0925) for Benralizumab (Fasenra) effective December 23, 2025. This policy establishes coverage criteria for asthma and eosinophilic granulomatosis with polyangiitis (EGPA) with mandatory precertification requirements, specialty prescriber restrictions (allergist/immunologist or pulmonologist for asthma), and specific clinical thresholds including eosinophil counts and prior biologic drug history. Billing teams must implement prior authorization workflows immediately and ensure claims include required clinical documentation.